Abstracts tagged "CD123"

Abstract Number: 1064 • ACR/ARP Annual Meeting 2019
CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy
Ross Lindsay¹, Janice Chen ¹, Robert Spiera ², Jessica Gordon ², Marie-Dominique Ah Kioon ³, Franck Barrat ³ and Christopher Brooks ¹, ¹Stemline Therapeutics, New York, ²Hospital for Special Surgery, New York, NY, ³HSS Research Institute, Hospital for Special Surgery, New York
Background/Purpose: Tagraxofusp is a novel targeted therapy directed to the interleukin-3 receptor (CD123). Tagraxofusp is comprised of human IL-3 recombinantly fused to a truncated diphtheria…